Acumen Pharmaceuticals, Inc. (ABOS): Price and Financial Metrics
GET POWR RATINGS... FREE!
ABOS Stock Price Chart Interactive Chart >
ABOS Price/Volume Stats
|Current price||$6.57||52-week high||$10.97|
|Prev. close||$5.33||52-week low||$3.02|
|Day high||$6.66||Avg. volume||72,526|
|50-day MA||$5.71||Dividend yield||N/A|
|200-day MA||$5.51||Market Cap||266.10M|
Acumen Pharmaceuticals, Inc. (ABOS) Company Bio
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapeutics for the treatment of Alzheimer's and other neurodegenerative diseases. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, which is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is based in Charlottesville, Virginia.
Most Popular Stories View All
ABOS Latest News Stream
|Loading, please wait...|
ABOS Latest Social Stream
View Full ABOS Social Stream
Latest ABOS News From Around the Web
Below are the latest news stories about ACUMEN PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ABOS as an investment opportunity.
Here is how Novo Nordisk (NVO) and Acumen Pharmaceuticals, Inc. (ABOS) have performed compared to their sector so far this year.
CHARLOTTESVILLE, Va. and CARMEL, Ind., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of novel targeted therapeutics for Alzheimer’s disease (AD), today announced Derrell Porter, M.D., has joined its Board of Directors. “We are thrilled to welcome Dr. Porter to our Board of Directors at a time when we’re rapidly advancing clinical development of ACU193,” said Daniel O
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q3 2022 Earnings Call Transcript November 14, 2022 Acumen Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.26 EPS, expectations were $-0.23. Operator: Good day. Thank you for standing by. Welcome to the Acumen Pharmaceuticals, Q3 2022 Conference Call and Webcast. At this time, all participants are in a listen-only […]
In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Acumen Pharmaceuticals (ABOS - Research Report), with a price target of $15.00. The company's shares closed yesterday at $6.14.According to TipRanks, Fein is an analyst with an average return of -10.4% and a 35.25% success rate. Fein covers the Healthcare sector, focusing on stocks such as Wave Life Sciences, Unity Biotechnology, and ACADIA Pharmaceuticals.The word on The Street in general, suggests a Strong Buy analyst consensus rating for Acumen Pharmaceuticals with a $17.20 average price target, which is a 180.13% upside from current levels.
INTERCEPT-AD, a Phase 1 clinical trial of ACU193 in patients with early Alzheimer’s disease continues to progress Acumen anticipates completing enrollment in the first quarter of 2023 and reporting topline data from this trial in the second half of 2023 ACU193 was granted Fast Track designation from the U.S. FDA for the treatment of early Alzheimer’s diseaseCash, cash equivalents and marketable securities of $200.2 million as of Sept. 30, 2022 expected to be sufficient to support clinical and op
ABOS Price Returns